迪哲医药2024年财报：全年营收3.6亿元，同比增长294%

Core Insights - Dize Pharmaceutical reported a significant increase in revenue for 2024, achieving 360 million yuan, a 294% year-on-year growth, and for Q1 2025, revenue reached 160 million yuan, marking a 96% increase [1] - The company made breakthroughs in commercialization and innovative R&D, with its core products, Shuwotini tablets and Golixitini capsules, included in the new national medical insurance catalog, leading to substantial sales growth [1] - The new drug application for Shuwotini has been accepted by the FDA for priority review, indicating the potential for global market entry [1] Financial Performance - In 2024, the net loss attributable to shareholders was approximately 850 million yuan, a 24% reduction year-on-year, while Q1 2025 saw a net loss of about 190 million yuan, a 14% decrease [1] - The sales expense ratio for Q1 2025 was 77%, significantly down from 124% for the entire year of 2024, reflecting improved operational efficiency [1] Strategic Outlook - The CEO emphasized the company's commitment to maximizing the commercial potential of its products and enhancing shareholder returns through efficient operations [2] - The company plans to optimize R&D resource allocation and accelerate clinical development of its product pipeline to provide safer and more effective treatment options for patients [2]